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Abstract
Background: In 2009, nearly half (289,756) of global re-treatment TB notifications are from India; no nationally-
representative data on the source of previous treatment was available to inform strategies for improvement of initial TB
treatment outcome.
Objectives: To assess the source of previous treatment for re-treatment TB patients registered under India’s Revised
National TB control Programme (RNTCP).
Methodology: A nationally-representative cross sectional study was conducted in a sample of 36 randomly-selected
districts. All consecutively registered retreatment TB patients during a defined 15-day period in these 36 districts were
contacted and the information on the source of previous treatment sought.
Results: Data was collected from all 1712 retreatment TB patients registered in the identified districts during the study
period. The data includes information on 595 ‘relapse’ cases, 105 ‘failure’ cases, 437 ‘treatment after default (TAD)’ cases and
575 ‘re-treatment others’ cases. The source of most recent previous anti-tuberculosis therapy for 754 [44% (95% CI, 38.2%–
49.9%)] of the re-treatment TB patients was from providers outside the TB control programme. A higher proportion of
patients registered as TAD (64%) and ‘retreatment others’ (59%) were likely to be treated outside the National Programme,
when compared to the proportion among ‘relapse’ (22%) or ‘failure’ (6%). Extrapolated to national registration, of the
292,972 re-treatment registrations in 2010, 128,907 patients would have been most recently treated outside the national
programme.
Conclusions: Nearly half of the re-treatment cases registered with the national programme were most recently treated
outside the programme setting. Enhanced efforts towards extending treatment support and supervision to patients treated
by private sector treatment providers are urgently required to improve the quality of treatment and reduce the numbers of
patients with recurrent disease. In addition, reasons for the large number of recurrent TB cases from those already treated
by the national programme require urgent detailed investigation.
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Introduction
The primary aim of the tuberculosis (TB) control programmes
across the world is to reduce mortality and morbidity due to TB by
interrupting the chain of TB transmission [1]. Re-treatment cases
(TB Patients who have been previously treated with anti-TB drugs
for at least a month), are a challenge to this primary aim of the TB
control Programmes. When compared to new cases, re-treatment
cases require longer and more complicated treatment, are more
likely harbour & transmit drug-resistant TB, and are likely to have
poor treatment outcomes, including increased risk of death [2,3].
In 2009, 622,342 (10%) of the 6.12 million global total TB
notifications million were re-treatment TB cases. India is estimated
to have more than one-fifth of the global TB burden. India,
however, disproportionately accounts for nearly half of re-
treatment TB cases notified globally, with 289,756 notified re-
treatment cases in 2009 [4]. The notification rate of re-treatment
TB in India has slowly but steadily increased over the past decade,
from 14 cases per 100,000 population in 2001 to 25 cases per
100,000 population in 2009 [5].
Re-treatment cases emerge mostly as a result of inadequate and
improper treatment of the new-TB cases, but TB treatment is
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with or without a prescription. Very little data has been reported
on the source of previous treatment for re-treatment cases under
programmatic conditions; only one small study from 2003 in
Rajasthan, North India, reported more than 85% of the
retreatment cases studied were previously treated in the private
sector [6].
The knowledge on the proportion of patients previously treated
in the non-RNTCP sector will assist the programme to interpret
the implication of the increasing notification of re-treatment cases.
It is unclear to what extent re-treatment cases notified represents a
warning sign regarding long term treatment outcomes under
RNTCP, or to what extent this represents the influence of
treatment of TB patients by the private sector. Hence, we
undertook nationally representative survey to assess the source of
previous treatment for re-treatment TB patients registered under
India’s RNTCP.
Methods
Study setting
The Government of India’s Revised National TB Control
Programme (RNTCP), based on the internationally recommended
Directly Observed Treatment Short-course (DOTS) strategy, was
launched in 1997, expanded across the country in a phased
manner and full nationwide coverage was achieved in March
2006. TB cases are diagnosed, categorized and treated with thrice-
weekly intermittent treatment regimens as per the standard WHO
treatment guidelines [3,7]. Health care in India is provided by
both public and huge non-public sector health facilities and TB
patients are diagnosed and managed both in the public as well in
the non-public health sector facilities [8]. Patients from the public
sector are usually managed under the programmatic setting as
specified under RNTCP guidelines and are part of the TB
notification system in India. RNTCP has made major efforts to
involve non-public health sector facilities, but many patients
(unknown magnitude) are still managed outside the programmatic
setting. Those in the private sector may or may not be managed as
per programmatic guidelines and are outside the TB notification
system of the country. The present study deals with the patients
notified under RNTCP.
Study design, sample size, sampling and study
population
We designed a nationally-representative cross-sectional study,
with cluster sampling, districts being the primary sampling units
(Clusters) and 100% enrolment of re-treatment patients in selected
districts for a fixed enrolment window. In the absence of reliable
estimates, we assumed that 50% of the re-treatment cases would
have previously been treated under RNTCP. A sample size of 880
patients was selected to estimate a 50% prevalence with a precision
of 65%, considering a 10% non-response rate and with a design
effect of 2 to account for cluster sampling. There were 650 districts
in the country with varying population sizes and numbers of re-
treatment TB patients registered. We selected 36 districts by
population proportionate to size sampling methodology. Based on
notification rates, a 15 day enrolment period was considered
sufficient to achieve the desired sample size. The study population
were all TB cases that were registered as re-treatment TB cases
during the study period.
Definitions of study variables
As routine programme practice, after the diagnosis of TB, every
TB patient is asked about the history of TB treatment by the
treating medical officer which includes reviewing previous medical
records and asking if s/he has ever taken treatment for TB,
injections for more than one or two weeks (streptomycin is likely),
or taken a medicine, which turned the urine orange–red
(rifampicin is likely). In addition to this, patients are also informed
that hiding her/his past treatment for TB, will result in wrong
treatment which can lead to failure of treatment and even death. A
retreatment TB patient under RNTCP is defined as a TB patient
who has taken anti-tuberculosis drugs for more than one month
from any source. If previously treated, the details on the year of
treatment, duration of treatment, drugs taken and source of
treatment (RNTCP/non-RNTCP) are recorded on the treatment
cards of the TB patients [9].
Re-treatment TB patients are further classified by the treating
medical officer at the time of treatment initiation into one of 4
registration groups: ‘relapse’ (a TB patient who was declared cured
or treatment completed by a physician in the past, but who reports
back to the health service and is now found to be sputum smear-
positive), ‘treatment after failure’ (a TB patient who is smear-
positive at 5 months or more after starting treatment and also a
initial smear negative TB patient who turns out to be smear
positive is also considered as a failure), ‘treatment after default
(TAD)’, (a TB patient who received anti-tuberculosis treatment for
one month or more from any source and returns to treatment after
having defaulted, i.e., not taken anti-TB drugs consecutively for
two months or more, and is found to be sputum smear-positive) or
‘re-treatment others’ (retreatment TB patients who do not fit into
the above mentioned types).
All types of re-treatment TB patients are treated with a thrice-
weekly fully-intermittent re-treatment regimen of 8 to 9 months
duration under direct observation. The first three months of
intensive phase consists of approximately two months (24 doses)
with 5 drugs [Isonaizid (H), rifampicin (R), pyrazinamide (Z),
ethambutol (E) and streptomycin (S)] followed by one month (12
doses) of four drugs (H,R,Z,E). If the patient is sputum smear
positive at the end of 3 months (36 doses) , the intensive phase is
extended for another month (12 doses) with H,R,Z,E. Irrespective
of the sputum smear status at the end of extended intensive phase,
the continuation phase with three drugs (H,R,E) is started and
continued for 5 months (66 doses). All patients initiated on
treatment are registered in a TB register maintained by a
paramedical worker (Senior TB Supervisor).
Data collection
The data was collected by a paramedical Senior TB Supervisors
by interviewing the re-treatment TB patients at the time of
registration and cross verified by the local Medical Officers and
programme managers. In addition, Medical consultants of the
WHO-RNTCP technical assistance project cross verified by
interviewing 10% of the data collected by the district programme
staff. Given the large, decentralized nature of data collection, and
based on the experiences during pre-testing of the study
methodology and the data collection sheet, the variables on which
the data was collected was kept fairly simple. The data was
collected on the most recent source of previous treatment; whether
it was ‘under RNTCP’ or ‘non-RNTCP’, the age, sex, type of re-
treatment TB. Patients were considered to be previously treated
under RNTCP, if they could recollect that they were treated from
a ‘patient wise box’ by visiting a DOT Provider thrice weekly or if
they possessed a ‘patient identity card’ provided by RNTCP or if
the ‘treatment supervisors’ were able to identify a TB registration
number under which these were previously treated by cross-
verifying the program records or by reviewing the medical records.
In the absence of any of this evidence of drug intake from
Previous Treatment for Retreatment TB, India
PLoS ONE | www.plosone.org 2 July 2011 | Volume 6 | Issue 7 | e22061RNTCP, patients were considered to be previously treated by
‘non-RNTCP sources’.
Ethical Considerations
The protocol was reviewed and approved by Central TB
Division, Ministry of Health and Family Welfare, Government of
India. As per programme guidelines, the history of previous
treatment needs to be elicited from every patient and recorded in a
systematic manner on the treatment cards. This study used the
same procedure to collect the data from the patients. Since the
study collected the data from an established practice as per the
programme guidelines, within the framework of routine care,
individual patient consent was deemed unnecessary by The
Central TB Division.
Data entry and analysis
Data collected from the field by the investigators were entered
into a pre-structured format in Microsoft Excel, cross verified by
the District TB Officers and then sent to Central TB Division. At
Central TB Division, data from individual districts was compiled
from all the 36 districts. Data was analysed using Epi Info (TM)
Version 3.5.1. Complex sample analysis was done with districts as
the primary sampling units to account from cluster sampling
methodology. Variables are summarized by proportions and 95%
confidence intervals (95% CI). Differences between sub-groups are
measured by chi-square tests.
Results
During a 15 day period 16
th May–31
st May, 2010, in the 36
selected districts a total of 1712 re-treatment patients were
registered, and all 1712 were enrolled. For operational reasons
one district collected data from all consecutively registered patients
from 1
st August–15
th August, 2010. The Medical Consultants of
the WHO-RNTCP technical assistance project re-visited 181
patients, cross verified the data collected and there was only one
case in which as error was noticed in recording the source of
previous treatment.
Seventy percent of the re-treatment cases were males (95% CI;
66.6%–73.4%), with 66% in the age-group of 25–54 years.
Patients classified as registration type ‘relapse’ and ‘others’
represented two-thirds of the patients registered, one-fourth were
TAD, and the remaining 6% were classified as ‘treatment after
failure’ re-treatment registrations. The source of most recent
previous anti-tuberculosis therapy for 56% (95% CI; 50.1%–
61.8%) of the retreatment cases was from RNTCP and the
remaining from non-RNTCP sources (Table 1). There were no
age and sex differences between those previously treated under
RNTCP and non-RNTCP sources. ‘Relapse’ and ‘failure’ cases
are more likely to have been previously treated under RNTCP and
‘TAD’ and ‘re-treatment other’ are more likely to have been
previously treated from Non-RNTCP sources (Table 2).
Discussion
Half of global TB re-treatment notifications are from India [4],
and reasons for this disproportionate contribution require
investigation. This is the first nationally representative operational
research study on the source of previous treatment for re-
treatment TB patients registered under the programme in India.
Nearly half (44%) of the re-treatment TB patients registered under
the RNTCP in India were previously treated from ‘non-RNTCP
sources’. The study findings have the following implications on the
TB control efforts in the country.
First, extrapolated to national registration, of the 292,972 re-
treatment registrations in 2010, 128,907 (95% CI, 111,915–
146,193) patients would have been most recently treated outside
the national programme. This key finding provides a direct
measure quantifying a part of the large number of TB cases
diagnosed and managed outside the national TB programme.
Tremendous efforts have been made by the programme to involve
all types of health care providers in the country in an attempt to
reach out to all the TB patients and substantial successes have
been achieved with the involvement of large numbers of medical
colleges, non-governmental organisation health facilities, and
other public sector hospitals [5,8,10]. The study findings however,
suggest that much more efforts are still needed.
Second, treating re-treatment TB patients is challenging due to
high levels of default [11] and prevalence of MDR-TB [12] and
only 70% of registered re-treatment TB cases are successfully
treated under programmatic setting. Ensuring early diagnosis of
new TB patients and its prompt treatment’ under programmatic
setting is the epidemiological basis of TB control strategy and the
only known cost effective measure to break the chain of TB
transmission for the control of tuberculosis. This is the basis of the
WHO recommended DOTS strategy and also the present global
strategy to stop TB [1]. The responsibility for participating in
organised TB control efforts also rests with all health care
providers who manage TB patients as per the International
Standards of TB Care [13]. All stakeholders associated with
Tuberculosis control must realise the importance of preventing
‘new’ cases from becoming ‘retreatment’ TB cases.
Third, morethan half of the patients were most recentlypreviously
treated from within the RNTCP. Thisraises questions about the long
term efficacy of short-course chemotherapy in the programme
Table 1. Demographic characteristics and source of previous
treatment of re-treatment TB patients registered under RNTCP
in India, 2010 (n=1712).
Variable
Frequency
N (%) 95% CI
Age distribution
,15 years 34 (2.0) 1.3–2.7
15–24 yrs 287(16.8) 13.7–19.9
25–34 Yrs 395 (23.1) 20.8–25.4
35–44 yrs 398 (23.2) 21.2–25.3
45–54 Yrs 345 (20.2) 17.3–23.0
55–64 yrs 166(9.7) 7.6–11.8
$65 yrs 87 (5.1) 3.6–6.5
Sex
Female 514 (30.0) 26.6–33.4
Male 1198 (70.0) 66.6–73.4
Type of TB
Relapse 595 (34.8) 27.7–41.8
Failure 105 (6.1) 4.6–7.7
TAD 437 (25.5) 20.7–30.3
Others 575 (33.6) 25.2–42.0
Previous treatment source
Non RNTCP 754 (44.0) 38.2–49.9
RNTCP 958 (56.0) 50.1–61.8
doi:10.1371/journal.pone.0022061.t001
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in identifying patients with residual disease below the threshold of
microscopy detection. In addition, ,2% of the sputum smearpositive
TB patients are declared as ‘treatment completed’ without having
undergone end of treatment follow-up sputum smear examination
[5]. In perspective, a huge cohort of morethan 12 million TB patients
hasbeentreated underthe programmesince its implementation. This
study provides no insight into the rate of long-term TB treatment
success or failure of the treatment regimen and appropriateness of the
programmatic processes adopted by RNTCP in treating patients and
in declaring treatment outcomes. To address this concern, the
programme should study long term treatment outcomes of TB
patients treated with fully intermittent short-course chemotherapy
under programmatic conditions.
Fourth, retreatment tuberculosis patients classified as ‘TAD’
and ‘retreatment-others’ are more likely to have been treated
outside the programmatic setting. While ‘TAD’ cases are sputum
smear positive pulmonary TB cases, ‘re-treatment others’ could be
sputum smear negative or extra-pulmonary TB cases. A previous
study in India had showed that a vast majority (84%) of the ‘re-
treatment others’ were sputum smear negative pulmonary TB
cases with relatively better treatment outcomes than sputum smear
positive re-treatment TB cases [14].
Finally, the influence of known risk factors for poor long term
treatment outcomes will have to be considered; as the prevalence
of irregular drug intake at the time of tuberculosis treatment,
tobacco usage, diabetes, HIV infection and malnutrition, and
other risk factors is likely to affect long term treatment efficacy
rates [15–18]. Measure to address these known risk factors, needs
to be incorporated within the programme framework.
Limitations
As in all research studies, there a few limitations in the present
studythat needsto beconsidered whileacceptingthedata.First,this
study is from patients were registered for treatment under RNTCP.
We believe that a large number of TB patients (unknown
magnitude) in India are treated outside the programmatic setting
[19]. This study only represents patients who registered for
treatment under RNTCP and not outside RNTCP. The choice of
health provider and source of re-treatment chosen by the patients
may have affected the profile of re-treatment TB patients registered
under the programme.There is no information on themagnitude of
TB patients who prefer to be treated from the same source or a
different source. Second, the past treatment profile of re-treatment
TB patients is affected by the number and different types of health
care providers offering TB treatment services in any given area and
the reach of RNTCP to these different types of the health care
providers. Third, we chose a 15 day period for data collection based
on operational feasibility and not randomly. If there are seasonal
changes in seeking health care from RNTCP, then this profile may
be different. Lastly, the study was done in a programmatic setting
and all the study investigators are linked with the programme. They
may have their own inherent biases when it comes to deciding on
the source of previous treatment for any patient. In order to
minimise classification and recall bias, limited information on only
the most recent source of previous treatment was collected. The
data was cross-verified by the local programme mangers, and the
additional sample re-verified by WHO-RNTCP medical consul-
tants suggested high accuracy in initial classification. Hence
misclassification of results did not likely affect our key findings.
Conclusions
Nearly half of the re-treatment TB cases registered under
RNTCP for treatment were previously treated from non-RNTCP
sources. There are no age and sex differentials in the source of
most recent previous treatment. Among retreatment-TB types,
‘relapses’ and ‘failures’ are more likely to have been treated under
RNTCP and ‘treatment after default’ and ‘re-treatment others’ are
likely to have been previously treated from non-RNTCP sources.
Recommendations
This study can form the starting point for a useful conversation to
address the challenges of re-treatment TB patients in India, which
has a substantial implication for the global TB control. Enhanced
efforts towards extending treatment support and supervision to
patients treated by private sector treatment providers are urgently
required to improve the quality of treatment and reduce the
numbers of patients with recurrent disease. In addition, reasons for
the large number of recurrent TB cases from those already treated
by the national programme require urgent detailed investigation.
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Table 2. Association between demographic variables and
type of TB with the history of previous source of treatment,
India.
Variable Non RNTCP RNTCP TOTAL
Chi square
test P value
Sex n % n %
Female 240 47% 274 53% 514 P=0.1480
Male 514 43% 684 57% 1198
Age
,15 years 14 41% 20 59% 34 P=0.3973
15–24 yrs 129 45% 158 55% 287
25–34 Yrs 181 46% 214 54% 395
35–44 yrs 165 41% 233 59% 398
45–54 Yrs 141 41% 204 59% 345
55–64 yrs 84 51% 82 49% 166
.65 yrs 40 46% 47 54% 87
Type of TB
Relapse 133.0 22% 462 78% 595 Referent
Failure 6.0 6% 99 94% 105 0.00008
TAD 278.0 64% 159 36% 437 0.00000
Others 337.0 59% 238 41% 575 0.00000
doi:10.1371/journal.pone.0022061.t002
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